Aquestive Therapeutics (NASDAQ:AQST) Coverage Initiated at Piper Sandler

Analysts at Piper Sandler assumed coverage on shares of Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) in a report issued on Thursday, MarketBeat.com reports. The firm set an "overweight" rating and a $10.00 price target on the stock. Piper Sandler's target price would suggest a potential upside of 144.50% from the stock's current price.

Several other brokerages have also recently commented on AQST. JMP Securities lifted their price objective on shares of Aquestive Therapeutics from $8.00 to $10.00 and gave the company an "outperform" rating in a research note on Friday, March 15th. HC Wainwright reaffirmed a "buy" rating and set a $9.00 price objective on shares of Aquestive Therapeutics in a research note on Friday, April 5th. Finally, Raymond James initiated coverage on shares of Aquestive Therapeutics in a report on Thursday, March 28th. They set an "outperform" rating and a $7.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Aquestive Therapeutics currently has a consensus rating of "Buy" and an average price target of $8.00.

Aquestive Therapeutics Trading Up 0.5 %

Shares of NASDAQ:AQST traded up $0.02 on Thursday, hitting $4.09. 2,842,184 shares of the company were exchanged, compared to its average volume of 2,143,406. The firm has a market capitalization of $299.80 million, a P/E ratio of -29.21 and a beta of 2.87. Aquestive Therapeutics has a 1-year low of $1.10 and a 1-year high of $6.23. The stock's 50 day moving average price is $3.87 and its 200 day moving average price is $2.60.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last issued its earnings results on Tuesday, March 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.04). The company had revenue of $13.21 million during the quarter, compared to the consensus estimate of $11.79 million. On average, equities analysts predict that Aquestive Therapeutics will post -0.35 EPS for the current fiscal year.

Insider Buying and Selling at Aquestive Therapeutics

In other news, insider Alexander Mark Schobel sold 25,000 shares of the company's stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $5.19, for a total transaction of $129,750.00. Following the completion of the transaction, the insider now directly owns 1,040,371 shares of the company's stock, valued at approximately $5,399,525.49. The sale was disclosed in a filing with the SEC, which is available at this link. 8.39% of the stock is owned by corporate insiders.

Institutional Trading of Aquestive Therapeutics

Several institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in Aquestive Therapeutics by 11.2% in the 4th quarter. Vanguard Group Inc. now owns 1,889,053 shares of the company's stock valued at $3,816,000 after buying an additional 190,401 shares in the last quarter. Goldman Sachs Group Inc. acquired a new position in shares of Aquestive Therapeutics during the fourth quarter valued at approximately $62,000. Virtu Financial LLC purchased a new position in shares of Aquestive Therapeutics in the fourth quarter valued at approximately $65,000. Bridgeway Capital Management LLC lifted its position in shares of Aquestive Therapeutics by 30.4% in the fourth quarter. Bridgeway Capital Management LLC now owns 192,856 shares of the company's stock valued at $390,000 after acquiring an additional 45,000 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Aquestive Therapeutics by 39.2% in the fourth quarter. Northern Trust Corp now owns 91,192 shares of the company's stock worth $184,000 after acquiring an additional 25,692 shares during the last quarter. Institutional investors and hedge funds own 32.45% of the company's stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.